A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Summary

Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.

Timeline

Start

2022-05-25

Primary completion

2022-12-01

Completion

2022-12-01

Outcome

Outcome not reported

Stopped (Business): “Study terminated due to business priorities”

Drugs

Indications